Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/AKT2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/AKT2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/AKT2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/AKT2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/AKT2_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/AKT2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/AKT2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006091 | Colorectum | AD | generation of precursor metabolites and energy | 209/3918 | 490/18723 | 3.17e-28 | 6.61e-25 | 209 |
GO:0015980 | Colorectum | AD | energy derivation by oxidation of organic compounds | 143/3918 | 318/18723 | 2.78e-22 | 2.49e-19 | 143 |
GO:0072659 | Colorectum | AD | protein localization to plasma membrane | 122/3918 | 284/18723 | 2.86e-17 | 1.49e-14 | 122 |
GO:0009896 | Colorectum | AD | positive regulation of catabolic process | 180/3918 | 492/18723 | 4.33e-16 | 1.94e-13 | 180 |
GO:0031331 | Colorectum | AD | positive regulation of cellular catabolic process | 156/3918 | 427/18723 | 4.68e-14 | 1.05e-11 | 156 |
GO:1990778 | Colorectum | AD | protein localization to cell periphery | 129/3918 | 333/18723 | 5.51e-14 | 1.15e-11 | 129 |
GO:1903829 | Colorectum | AD | positive regulation of cellular protein localization | 110/3918 | 276/18723 | 4.58e-13 | 8.44e-11 | 110 |
GO:0090150 | Colorectum | AD | establishment of protein localization to membrane | 100/3918 | 260/18723 | 6.01e-11 | 6.33e-09 | 100 |
GO:0048732 | Colorectum | AD | gland development | 149/3918 | 436/18723 | 6.07e-11 | 6.33e-09 | 149 |
GO:1905475 | Colorectum | AD | regulation of protein localization to membrane | 73/3918 | 175/18723 | 3.37e-10 | 2.93e-08 | 73 |
GO:1904951 | Colorectum | AD | positive regulation of establishment of protein localization | 112/3918 | 319/18723 | 2.55e-09 | 1.80e-07 | 112 |
GO:0051222 | Colorectum | AD | positive regulation of protein transport | 106/3918 | 303/18723 | 8.45e-09 | 5.08e-07 | 106 |
GO:0006605 | Colorectum | AD | protein targeting | 105/3918 | 314/18723 | 1.39e-07 | 6.44e-06 | 105 |
GO:1905477 | Colorectum | AD | positive regulation of protein localization to membrane | 46/3918 | 106/18723 | 1.47e-07 | 6.64e-06 | 46 |
GO:0016050 | Colorectum | AD | vesicle organization | 101/3918 | 300/18723 | 1.65e-07 | 7.17e-06 | 101 |
GO:0090316 | Colorectum | AD | positive regulation of intracellular protein transport | 62/3918 | 160/18723 | 1.82e-07 | 7.79e-06 | 62 |
GO:0032388 | Colorectum | AD | positive regulation of intracellular transport | 74/3918 | 202/18723 | 1.83e-07 | 7.80e-06 | 74 |
GO:0032868 | Colorectum | AD | response to insulin | 91/3918 | 264/18723 | 2.02e-07 | 8.48e-06 | 91 |
GO:0032386 | Colorectum | AD | regulation of intracellular transport | 109/3918 | 337/18723 | 5.33e-07 | 1.95e-05 | 109 |
GO:0033157 | Colorectum | AD | regulation of intracellular protein transport | 80/3918 | 229/18723 | 5.81e-07 | 2.09e-05 | 80 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa050173 | Colorectum | SER | Spinocerebellar ataxia | 46/1580 | 143/8465 | 6.78e-05 | 7.51e-04 | 5.45e-04 | 46 |
hsa049193 | Colorectum | SER | Thyroid hormone signaling pathway | 40/1580 | 121/8465 | 1.02e-04 | 1.06e-03 | 7.67e-04 | 40 |
hsa052053 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
hsa051703 | Colorectum | SER | Human immunodeficiency virus 1 infection | 58/1580 | 212/8465 | 1.08e-03 | 8.56e-03 | 6.21e-03 | 58 |
hsa047283 | Colorectum | SER | Dopaminergic synapse | 37/1580 | 132/8465 | 5.27e-03 | 3.28e-02 | 2.38e-02 | 37 |
hsa049151 | Colorectum | SER | Estrogen signaling pathway | 38/1580 | 138/8465 | 6.51e-03 | 3.68e-02 | 2.67e-02 | 38 |
hsa040153 | Colorectum | SER | Rap1 signaling pathway | 54/1580 | 210/8465 | 6.55e-03 | 3.68e-02 | 2.67e-02 | 54 |
hsa054173 | Colorectum | SER | Lipid and atherosclerosis | 55/1580 | 215/8465 | 6.83e-03 | 3.77e-02 | 2.74e-02 | 55 |
hsa042133 | Colorectum | SER | Longevity regulating pathway - multiple species | 20/1580 | 62/8465 | 7.15e-03 | 3.77e-02 | 2.74e-02 | 20 |
hsa051633 | Colorectum | SER | Human cytomegalovirus infection | 57/1580 | 225/8465 | 7.40e-03 | 3.84e-02 | 2.79e-02 | 57 |
hsa052084 | Colorectum | MSS | Chemical carcinogenesis - reactive oxygen species | 118/1875 | 223/8465 | 2.71e-24 | 4.54e-22 | 2.78e-22 | 118 |
hsa050104 | Colorectum | MSS | Alzheimer disease | 169/1875 | 384/8465 | 1.21e-22 | 1.01e-20 | 6.21e-21 | 169 |
hsa054154 | Colorectum | MSS | Diabetic cardiomyopathy | 106/1875 | 203/8465 | 2.47e-21 | 1.62e-19 | 9.92e-20 | 106 |
hsa049324 | Colorectum | MSS | Non-alcoholic fatty liver disease | 85/1875 | 155/8465 | 4.19e-19 | 1.17e-17 | 7.17e-18 | 85 |
hsa051314 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
hsa051324 | Colorectum | MSS | Salmonella infection | 92/1875 | 249/8465 | 5.23e-08 | 9.74e-07 | 5.97e-07 | 92 |
hsa050174 | Colorectum | MSS | Spinocerebellar ataxia | 60/1875 | 143/8465 | 7.14e-08 | 1.26e-06 | 7.71e-07 | 60 |
hsa046664 | Colorectum | MSS | Fc gamma R-mediated phagocytosis | 45/1875 | 97/8465 | 9.30e-08 | 1.56e-06 | 9.55e-07 | 45 |
hsa051354 | Colorectum | MSS | Yersinia infection | 53/1875 | 137/8465 | 7.73e-06 | 8.93e-05 | 5.47e-05 | 53 |
hsa052102 | Colorectum | MSS | Colorectal cancer | 36/1875 | 86/8465 | 3.08e-05 | 3.22e-04 | 1.97e-04 | 36 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | CHEMBL2177390 | IPATASERTIB | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | | GDC-0068 | IPATASERTIB | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | allosteric modulator | 405560349 | | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | | TRICIRIBINE | TRICIRIBINE | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | 223366042 | CAPIVASERTIB | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | CHEMBL3545134 | LY-2780301 | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | 249565578 | IPATASERTIB | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | | AFURESERTIB HYDROCHLORIDE | | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | allosteric modulator | 249565628 | MK-2206 | |
208 | AKT2 | CLINICALLY ACTIONABLE, ENZYME, DRUGGABLE GENOME, TRANSPORTER, TRANSCRIPTION FACTOR, KINASE, SERINE THREONINE KINASE, TUMOR SUPPRESSOR | inhibitor | MK2206 | MK-2206 | |